Skip to main content
Top
Published in: Digestive Diseases and Sciences 11/2011

01-11-2011 | Original Article

Prodromal Irritable Bowel Syndrome May Be Responsible for Delays in Diagnosis in Patients Presenting with Unrecognized Crohn’s Disease and Celiac Disease, but Not Ulcerative Colitis

Authors: S. M. Barratt, J. S. Leeds, K. Robinson, A. J. Lobo, M. E. McAlindon, D. S. Sanders

Published in: Digestive Diseases and Sciences | Issue 11/2011

Login to get access

Abstract

Introduction

We aimed to determine the prevalence and duration of prodromal periods in patients with celiac disease and inflammatory bowel disease (Crohn’s disease and ulcerative colitis). Furthermore, we explored to what extent vague abdominal symptoms consistent with both disorders were attributed to irritable bowel syndrome (IBS) and if the presence of prodromal IBS (P-IBS) had an impact on prodrome duration.

Methods

In the study, 683 biopsy-proven patients (celiac n = 225, ulcerative colitis n = 228, Crohn’s disease n = 230) completed a postal survey including an assessment of prodromal periods and IBS symptoms during both the prodrome and at present (achieved by completion of the ROME II criteria). Results were compared to age/sex-matched controls (n = 348).

Results

Crohn’s disease patients had the highest prevalence of prodromes (94%) in comparison to ulcerative colitis (48%) and celiac disease (44%). However, Crohn’s disease patients have the lowest prevalence of P-IBS (29%) in comparison to ulcerative colitis (38%) and celiac disease (67%). Prodrome duration in patients with P-IBS Crohn’s disease was 4 years in comparison to 2 years without (p = 0.018). Prodrome duration in P-IBS celiac disease was 10 years in comparison to 7 years without (p = 0.046). Prodrome duration in patients with ulcerative colitis was not affected by P-IBS (p ≥ 0.05). Age and sex were not confounding factors.

Conclusions

This is the first study to make direct comparisons of prodrome periods between celiac disease and IBD. Prodrome duration in celiac disease is significantly longer and more often characterized by P-IBS than IBD. In celiac disease and CD, P-IBS increases prodrome duration. This may represent a failure to understand the overlap between IBS and celiac disease/IBD.
Literature
1.
go back to reference Sanders DS, Hurlstone D, Stokes R, Rashid F, Milford-Ward A, Hadjivassiliou M. Changing face of adult celiac disease: experience of a single university hospital in South Yorkshire. Postgrad Med J. 2002;78:31–33.PubMedCrossRef Sanders DS, Hurlstone D, Stokes R, Rashid F, Milford-Ward A, Hadjivassiliou M. Changing face of adult celiac disease: experience of a single university hospital in South Yorkshire. Postgrad Med J. 2002;78:31–33.PubMedCrossRef
2.
go back to reference Cranney A, Zarkadas M, Graham ID, et al. The Canadian Celiac Health Survey. Dig Dis Sci. 2007;52:1087–1095.PubMedCrossRef Cranney A, Zarkadas M, Graham ID, et al. The Canadian Celiac Health Survey. Dig Dis Sci. 2007;52:1087–1095.PubMedCrossRef
3.
go back to reference Pimentel M, Chang M, Chow E, et al. Identification of a prodrome period in Crohn’s disease but not ulcerative colitis. Am J Gastroenterol. 2000;95:3462–3558. Pimentel M, Chang M, Chow E, et al. Identification of a prodrome period in Crohn’s disease but not ulcerative colitis. Am J Gastroenterol. 2000;95:3462–3558.
4.
go back to reference Pieper C, Haag S, Gesenhues S, Gerken G, Jockel K. Guideline adherence, patient satisfaction in IBD—an evaluation study. BMC Health Serv Res. 2009;27:9–17. Pieper C, Haag S, Gesenhues S, Gerken G, Jockel K. Guideline adherence, patient satisfaction in IBD—an evaluation study. BMC Health Serv Res. 2009;27:9–17.
5.
go back to reference Burgmann T, Clara I, Graff L, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis—how much is irritable bowel syndrome? Clin Gastroenterol Hepatol. 2006;4:614–662.PubMedCrossRef Burgmann T, Clara I, Graff L, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis—how much is irritable bowel syndrome? Clin Gastroenterol Hepatol. 2006;4:614–662.PubMedCrossRef
6.
go back to reference Dickey W, McConnel J. How many hospital visits does it take before celiac sprue is diagnosed? J Clin Gastroenterol. 1996;23:21–23.PubMedCrossRef Dickey W, McConnel J. How many hospital visits does it take before celiac sprue is diagnosed? J Clin Gastroenterol. 1996;23:21–23.PubMedCrossRef
7.
go back to reference Lo W, Sano K, Lebwohl B, Diamond B, Green PH. Changing presentation of adult celiac disease. Dig Dis Sci. 2003;48:395–398.PubMedCrossRef Lo W, Sano K, Lebwohl B, Diamond B, Green PH. Changing presentation of adult celiac disease. Dig Dis Sci. 2003;48:395–398.PubMedCrossRef
8.
go back to reference Hauser W, Gold J, Stallmach A, Caspary WF, Stein J. Health-related quality of life in adult celiac disease in Germany: results of a national survey. Euro J Gastroenterol Hepatol. 2006;18:747–754.CrossRef Hauser W, Gold J, Stallmach A, Caspary WF, Stein J. Health-related quality of life in adult celiac disease in Germany: results of a national survey. Euro J Gastroenterol Hepatol. 2006;18:747–754.CrossRef
9.
10.
go back to reference Xavier R, Podolsky D. Unravelling the pathogenesis of IBD. Nature. 2007;427–435. Xavier R, Podolsky D. Unravelling the pathogenesis of IBD. Nature. 2007;427–435.
11.
go back to reference Thompson WG, Longstreth GF, Drossman DA. Functional bowel disorders and functional abdominal pain. GUT. 1999;45:1143–1147. Thompson WG, Longstreth GF, Drossman DA. Functional bowel disorders and functional abdominal pain. GUT. 1999;45:1143–1147.
12.
go back to reference Corazza GR, Brusco G, Andreani ML, Biagi F, Stefano MD, Gasbarrini G. Previous misdiagnosis, diagnostic delay in adult celiac sprue. J Clin Gastroenterol. 1996;22:324–325.PubMedCrossRef Corazza GR, Brusco G, Andreani ML, Biagi F, Stefano MD, Gasbarrini G. Previous misdiagnosis, diagnostic delay in adult celiac sprue. J Clin Gastroenterol. 1996;22:324–325.PubMedCrossRef
13.
go back to reference Mearin F, Badia X, Balboa A, et al. IBS prevalence varies enormously depending on the employed diagnostic criteria: comparison of ROME II versus previous criteria in a general population. Scand J Gastroenterol. 2001;36:1155–1161.PubMedCrossRef Mearin F, Badia X, Balboa A, et al. IBS prevalence varies enormously depending on the employed diagnostic criteria: comparison of ROME II versus previous criteria in a general population. Scand J Gastroenterol. 2001;36:1155–1161.PubMedCrossRef
14.
go back to reference Kumar P, Clarke M. Clinical Medicine. 5th ed. London: Churchill Livingstone. Kumar P, Clarke M. Clinical Medicine. 5th ed. London: Churchill Livingstone.
15.
go back to reference Zipser R, Farid M, Baisch D, Patel B, Patel D. Physician awareness of celiac disease: a need for further education. J Gen In Med. 2005;20:644–646. Zipser R, Farid M, Baisch D, Patel B, Patel D. Physician awareness of celiac disease: a need for further education. J Gen In Med. 2005;20:644–646.
16.
go back to reference O’Leary C, Wieneke P, Buckley S, O’Regan P, Cronin P, Quigley E. Celiac disease and irritable bowel-type symptoms. Am J Gastro. 2002;97:1463–1467.CrossRef O’Leary C, Wieneke P, Buckley S, O’Regan P, Cronin P, Quigley E. Celiac disease and irritable bowel-type symptoms. Am J Gastro. 2002;97:1463–1467.CrossRef
17.
go back to reference Keohane J, O’Mahony C, O’Mahony L, O’Mahony S, Quigley EM, Shanahan F. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or a reflection of occult inflammation? Am J Gastroenterol. 2010;105:1789–1794.CrossRef Keohane J, O’Mahony C, O’Mahony L, O’Mahony S, Quigley EM, Shanahan F. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or a reflection of occult inflammation? Am J Gastroenterol. 2010;105:1789–1794.CrossRef
18.
go back to reference Long MD, Drossman DA. Inflammatory bowel disease, irritable bowel syndrome, or what? A challenge to the functional-organic dichotomy. Am J Gastroenterol. 2010;105:1789–1794.CrossRef Long MD, Drossman DA. Inflammatory bowel disease, irritable bowel syndrome, or what? A challenge to the functional-organic dichotomy. Am J Gastroenterol. 2010;105:1789–1794.CrossRef
19.
go back to reference Mein SM, Ladabaum U. Serological testing for coeliac disease patients with symptoms of irritable bowel syndrome: a cost effectiveness analysis. Aliment Pharmacol Ther. 2004;19:1–12.CrossRef Mein SM, Ladabaum U. Serological testing for coeliac disease patients with symptoms of irritable bowel syndrome: a cost effectiveness analysis. Aliment Pharmacol Ther. 2004;19:1–12.CrossRef
20.
go back to reference Biesiekieski TR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomised placebo-controlled trial. Am J Gastroenterol. 2011;106:508–514.CrossRef Biesiekieski TR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomised placebo-controlled trial. Am J Gastroenterol. 2011;106:508–514.CrossRef
Metadata
Title
Prodromal Irritable Bowel Syndrome May Be Responsible for Delays in Diagnosis in Patients Presenting with Unrecognized Crohn’s Disease and Celiac Disease, but Not Ulcerative Colitis
Authors
S. M. Barratt
J. S. Leeds
K. Robinson
A. J. Lobo
M. E. McAlindon
D. S. Sanders
Publication date
01-11-2011
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 11/2011
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-011-1783-y

Other articles of this Issue 11/2011

Digestive Diseases and Sciences 11/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.